| Friday June 5 | |||
| 09:00-09:45 | Registration and coffee | ||
| 09:45-10:00 | Welcome and Introduction | ||
| Morning program | Chair: Jon Wakefield | ||
| 10:00-10:20 | Jon Wakefield | Bayesian individualization via sampling-based methods | |
| 10:20-10:40 | J Bennett, L Lacey, K Koch, A Bye | Determination of the population pharmacokinetics of bismuth from GR122311X in healthy volunteers using the gibbs sampler bayesian method | |
| 10:40-11:00 | L Harnisch, W Weber | Population approach to nonlinear pharmacokinetics of a new drug under development | |
| 11:00-11:20 | NJ Bruce, AH Thomson, HL Elliott | Population pharmacokinetics of tacrolimus in liver transplant patients | |
| 11:20-11:40 | M Karlsson, P Milligan, D Nichols | Determination of relative potency for drug and metabolite in vivo | |
| 11:40-12:00 | N Jonsson, JR Wade, G Almqvist, M Karlsson | Discrimination between rival dosing histories | |
| 12:00-13:45 | Lunch | ||
| Afternoon program | PK/PD | Chair: Leon Aarons: | |
| 13:45-14:10 | D Hille, R Bruno, S Durrleman, LB Sheiner | Relationship between the pharmacokinetics and the pharmacodynamics of taxotere in cancer patients | |
| 14:10-14:35 | K Fattinger, D Verotta, HC Porchet, A Munafo, J-Y le Cotonnec, LB Sheiner | Pharmacokinetic/-dynamic modeling of a bivariate control system: luteinizing hormone and testosterone response to GnRH antagonist antide | |
| 14:35-14:55 | C Laveille, N Frey, G Lerebours, G Resplandy, R Jochemsen | Population pharmacokinetic-pharmacodynamic of a new specific bradycardic agent: S-16257 | |
| 14:55-15:15 | S Marshall, HL Elliott, PA Meredith | Prediction of simvastatin pharmacological response: a population analysis | |
| 15:15-15:45 | Coffee break | ||
| Afternoon session II | Population Toxicokinetics and Scaling from animal to man | Chair: Eliane Fuseau | |
| 15:45-16:05 | P Burtin, J van Bree, F Mentre, S Hensel, JL Steimer | A prospective evaluation of sparse sampling for toxicokinetics in the course of drug development | |
| 16:05-16:25 | V Cosson, E Fuseau, C Efthymiopoulos, A Bye | From animal to man | |
| 16:25-16:45 | W Weber, L Harnisch, M Zimmer, P Crause, B Katgely | Optimization of a ''first dose in man study'' using a NONMEM model for mammals | |
| 16:45 - 17:30 | Discussions and questions | Chair: Lutz Harnisch | |
| 16:45-17:00 | F Keller, D Zellner, T Frankewitsch, M Giehl | Population kinetics and individual drug dosage adjustment | |
| 17:30-18:30 | Poster session I, Software demonstrations | ||
| 20:00-24:00 | Social Evening | ||
| Saturday June 10 | |||
| Tutorial I | Chair: France Mentré | ||
| 09:30-09:45 | H Hassani | Stochastic model in the analysis of migraine data | |
| 09:45-10:30 | F Rombout | An industrial perspective: practical stages in model development | |
| 10:30-11:00 | Coffee break | ||
| Tutorial II | Chair: Gudrun Wallenstein | ||
| 11:00-11:45 | L Aarons | Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies | |
| 11:45-12:00 | H-J Röthig, W Weber | Closing remarks | |
| 12:00-14:00 | Poster session II, software demonstrations | ||
Study design
1. D Breilh, C Pobel, MC Saux Non linear pharmacokinetics of ethanol Analysis of patients with NONMEM. study I
2. D Breilh, C Pobel, MC Saux Non linear pharmacokinetics of ethanol Population model with NONMEM after an optimal sampling duration. study II
3. B Charpiat, V Broant, G Tissier, JM Sab, P Maire, RW Jelliffe How many patients and blood levels for population pharmacokinetic analysis? a study with a one compartment model
4. AC Falcao, MM Fernandez de Gatta, A Dominguez-Gil, JM Lanao Sampling strategies for population analysis: a theoretical study to support practical results obtained with caffeine in premature neonates
5. NS Houwing, F Rombout Population pharmacokinetics: effect of sampling scheme on parameter estimation
Drug development
6. G Lockwood, G Maier The use of population pharmacokinetic approaches to aid in the assessment of bioequivalence for a highly variable drug
7. M Looby, U Wuenscher, M Weiss NONMEM in destructive sampling experiments: experiences with the toxicokinetics of dibromchloromethane
8. F Mesnil, F Mentre, C Dubruc, A Mallet Population pharmacokinetics analysis of mizolastine: estimation with NPML and validation
9. P Milligan, M Karlsson, D Nichols High variability compounds - high risk for developers?
10. JPR Monteleone, NHG Holford Modeling interoccasion variability in toxicokinetics and toxicodynamics
Data rich situations
11. R Schoemaker, A Cohen Estimation of kinetic/dynamic curves with insufficient information for each individual using non-linear mixed effect modelling
12. J Wade, B-M Emanuelsson, LL Gustafsson, M Karlsson A population approach enables the characterisation of saturable protein binding for Ropivacaine
13. W Weber, L Harnisch, M Zimmer, C Rokitta, P Mendes New evidence for a triexponential disposition of Cefotaxim
Software demonstrations
1. M Tod An algorithm for the estimation of optimal sampling times in pharmacokinetics by the ed, eid and api criteria
2. S Urien MP2 (Micropharm population): a Windows application for population pharmacokinetics
3. J Wakefield, G Strehlau Software product POPKAN; population pharmacokinetic modelling and analysis
PK/PD
14. D Breilh, C Pobel, C Roth, MC Saux, G Janvier Sufentanyl Pharmacokinetic-pharmacodynamic modeling (PK/PD) on NONMEM in 10 patients with coronary surgery
15. MJ du Preez, JH Botha, ML McFadyen, M Adhikari Effect concentration relationships of theophylline in apnoea of prematurity
16. S Rietbrock, S Harder, H Baas Influence of apomorphine on the PK/PD-relationship of levodopa: two-step versus NONMEM analysis
TDM
17. D Breilh, C Pobel, P Rispal, MC Saux Population of vancomycine with continuous infusion administered in neutropenic patients modeling on NPEEM2-NONMEM-P-PHARM
18. J Bres, D Cupissol, J Nouguier-Soule, C Gestin-Boyer, Ü Büttner, B Palomba Population distribution of platinum pharmacokinetic parameters for dosage recommendations of CDDP and adaptive control during the course of therapy, using different softwares
19. MT Mateu-Garcia, JJ Porez-Ruixo, VG Casabo-Alos, NV Jimenez-Torres Apache II as predictor of gentamicin pharmacokinetic parameters in critical ill patients
20. H Peyriere, J Bres, D Hillaire-Buys Performance evaluation of three softwares for bayesian predictions of teicoplanin pharmacokinetic parameters: Apis Micropharm, PKS Abbott
21. D Santos Buelga, MF Delgado Iribarnegaray, MJ Garca, MJ Otero, A Falcao, A Dominguez-Gil Carbamazepine population pharmacokinetics in children
22. M Tod, C Padoin, C Minozzi, J Cougnard, O Petitjean A population pharmacokinetic study of isepamicin in ICU patients
Oncology
23. LS Murray, DI Jodrell, JG Morrison, AW Kelman, DJ Kerr, B Whiting, SB Kaye A population approach to predicting post-treatment levels of epirubicin in patients with advanced breast cancer
24. M Sandström, A Freijs, R Larsson, P Nygren, J Bergh, M-L Fjollskog, M Karlsson Lack of relationship between systemic exposure for the component drugs of the FEC regimen in breast cancer patients
24. B Tranchand, S Urien, CJ Ardiet Population pharmacokinetics of intravenous melphalan: NONMEM and MP2 analysis